CA2928697C - Delivery of drugs - Google Patents

Delivery of drugs Download PDF

Info

Publication number
CA2928697C
CA2928697C CA2928697A CA2928697A CA2928697C CA 2928697 C CA2928697 C CA 2928697C CA 2928697 A CA2928697 A CA 2928697A CA 2928697 A CA2928697 A CA 2928697A CA 2928697 C CA2928697 C CA 2928697C
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
group
composition
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2928697A
Other languages
English (en)
French (fr)
Other versions
CA2928697A1 (en
Inventor
Ijeoma Uchegbu
Andreas Schatzlein
Lisa GODFREY
Katerina LALATSA
Antonio IANNITELLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanomerics Ltd
Original Assignee
Nanomerics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanomerics Ltd filed Critical Nanomerics Ltd
Publication of CA2928697A1 publication Critical patent/CA2928697A1/en
Application granted granted Critical
Publication of CA2928697C publication Critical patent/CA2928697C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2928697A 2013-11-04 2014-11-03 Delivery of drugs Active CA2928697C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1319437.8 2013-11-04
GBGB1319437.8A GB201319437D0 (en) 2013-11-04 2013-11-04 Delivery of drugs
PCT/GB2014/053254 WO2015063510A1 (en) 2013-11-04 2014-11-03 Delivery of drugs

Publications (2)

Publication Number Publication Date
CA2928697A1 CA2928697A1 (en) 2015-05-07
CA2928697C true CA2928697C (en) 2022-01-25

Family

ID=49767616

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2928697A Active CA2928697C (en) 2013-11-04 2014-11-03 Delivery of drugs

Country Status (6)

Country Link
US (1) US10213474B2 (https=)
EP (1) EP3065779B1 (https=)
JP (1) JP6486349B2 (https=)
CA (1) CA2928697C (https=)
GB (1) GB201319437D0 (https=)
WO (1) WO2015063510A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202007703D0 (en) 2020-05-22 2020-07-08 Nanomerics Ltd Amphiphilic carbohydrate compounds
MX2023002109A (es) * 2020-08-24 2023-07-13 Nanomerics Ltd Inhibidores virales.
US20250009676A1 (en) * 2021-10-06 2025-01-09 Purdue Pharma L.P. Compositions and methods for levodopa delivery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763393A (en) * 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
GB0221941D0 (en) 2002-09-20 2002-10-30 Univ Strathclyde Polysoaps
GB0315632D0 (en) * 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US8187570B1 (en) * 2005-01-04 2012-05-29 Gp Medical, Inc. Nanoparticles for protein drug delivery
GB0615834D0 (en) 2006-08-09 2006-09-20 Univ Glasgow Polymeric micellar clusters and their uses in formulating drugs
JP2009252275A (ja) * 2008-04-03 2009-10-29 Nec Electronics Corp 半導体記憶装置
TWI437007B (zh) 2008-07-24 2014-05-11 Food Industry Res & Dev Inst 於水相中製備幾丁聚醣奈米顆粒之方法
GB0903559D0 (en) * 2009-03-02 2009-04-08 Univ London Pharmacy Oral delivery of hydrophilic drugs to the brain
US10307372B2 (en) * 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP3269372B1 (en) * 2012-01-19 2019-06-12 Hybrid Medical, LLC Topical therapeutic formulations

Also Published As

Publication number Publication date
EP3065779A1 (en) 2016-09-14
JP2016539100A (ja) 2016-12-15
GB201319437D0 (en) 2013-12-18
WO2015063510A1 (en) 2015-05-07
CA2928697A1 (en) 2015-05-07
EP3065779B1 (en) 2019-06-26
JP6486349B2 (ja) 2019-03-20
US20160279189A1 (en) 2016-09-29
US10213474B2 (en) 2019-02-26

Similar Documents

Publication Publication Date Title
Guan et al. N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy
US9526705B2 (en) Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
US5629011A (en) Composition for nasal administration
JP5469458B2 (ja) 高分子ミセルクラスタ及びそれらの薬剤への使用
US10561733B2 (en) Process for producing nanoparticles laden with active ingredient
KR20120015294A (ko) 벤다무스틴 환형다당류 조성물
TW201302850A (zh) 新穎之嵌段共聚物、微胞調製物及將其作為有效成分之抗癌劑
US20120288491A1 (en) Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
Le-Deygen et al. Drug delivery systems for fluoroquinolones: New prospects in tuberculosis treatment
WO2012111627A1 (ja) プロスタグランジンｉ２誘導体を含有するナノ粒子
CA2928697C (en) Delivery of drugs
CN108191995A (zh) 一种还原敏感的两亲性多糖衍生物及其制备方法和用途
EP2042166A1 (en) Nanocapsules for oral delivery of proteins
WO2021108801A2 (en) Long acting nmda antagonists
EP3453390B1 (en) Polymerized drug-containing pharmaceutical composition
US12016865B2 (en) Methods and pharmaceutical compositions for treating candida auris in blood
CN117899084A (zh) 药物组合物、制剂、美托拉宗冻干粉制剂及其制备方法与用途
CN116987208B (zh) 一种pH响应分解的两亲性葡聚糖嵌段聚合物、阳离子抗菌肽纳米药物及应用
CN112741821B (zh) 一种唾液酸纳米颗粒及其制备方法和应用
Alastal et al. Research Article Enhancing Intranasal Delivery and Bioavailability of Dihydroergotamine Utilizing Chitosan Nanoparticles
TW201505636A (zh) 硼酸化合物之新穎製劑
Stieger et al. The use of dendrimers to optimize the physicochemical and therapeutic properties of drugs
CN119486761A (zh) 透明质酸衍生物药物组合物以及药物组合物
Xian Hydrophobically Modified Low Molecular Weight Chitosan for Drug Delivery
LT et al. Manufacturing Co. 11710 Naor (JO)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191009

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - SMALL

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241030

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241030

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241030

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - SMALL

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251015

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251015